igh cholesterol levels are known risk factors for cardiovascular morbidity, mortality, and atherosclerosis. Since the mid-1990s, statins have been the most important lipidlowering drugs (LLD) in primary and secondary prevention of cardiovascular disease. Statins have reduced the incidence of myocardial infarction and stroke in several randomized clinical trials. [1] [2] [3] [4] [5] [6] [7] [8] Carotid intima media thickness (IMT) and plaques assessed by ultrasound are established markers of carotid atherosclerosis, and are used as surrogates for cardiovascular disease. Randomized controlled trials and meta-analyses of randomized controlled trials have shown that statins slow the progression of intima media thickening.
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igh cholesterol levels are known risk factors for cardiovascular morbidity, mortality, and atherosclerosis. Since the mid-1990s, statins have been the most important lipidlowering drugs (LLD) in primary and secondary prevention of cardiovascular disease. Statins have reduced the incidence of myocardial infarction and stroke in several randomized clinical trials. [1] [2] [3] [4] [5] [6] [7] [8] Carotid intima media thickness (IMT) and plaques assessed by ultrasound are established markers of carotid atherosclerosis, and are used as surrogates for cardiovascular disease. Randomized controlled trials and meta-analyses of randomized controlled trials have shown that statins slow the progression of intima media thickening. 9, 10 A recent review indicates that statins may have beneficial effects also on plaque progression, but most of the included studies were small observational studies. 9 In a randomized controlled trial of rosuvastatin versus placebo in 492 low-risk patients, plaque progression was significantly lower in the statin group. 11 In a study on 4378 patients referred to stroke and atherosclerosis prevention clinics, the annual rate of plaque progression decreased after implementation of a more intensive medical therapy strategy, which included increase of statin to the maximum tolerated dose and addition of ezetimibe to patients already on maximum tolerated statin dose. 12 Although randomized clinical trial is gold standard for proving the effect of a given intervention, the generalizability may be limited. There is little knowledge on whether the effect of LLD on atherosclerosis progression seen in randomized clinical trials also applies to other practice settings. The purpose of the present study was to assess the impact of LLD on progression on carotid atherosclerosis in a general population.
The Tromsø study is a single-center, longitudinal population study with repeated surveys of the inhabitants of the municipality of Tromsø, Norway. We have repeatedly, over a period of 13 years, obtained information on the use of LLD and cardiovascular risk factors, and measured IMT and total plaque area (TPA) in the right carotid artery. 13 This enables assessment of the effect of use of LLD and change in carotid atherosclerosis in unselected subjects belonging to a general population.
Materials and Methods
Materials and Methods are available in the online-only Supplement. Table 1) . At baseline, in 1994 to 1995, the proportion of current LLD users among the study participants was low 1.6% (n=51). In the 6th survey (2007) (2008) , the percentage of current users had risen to 27% (n=799). At baseline, 89% of those who reported brand names (n=46) used statins, the rest used cholestyramine. At follow-up, all who reported brand names (n=713) used statins, whereas only 4 persons used ezetimib. Use of LLD was associated with male sex, higher age, systolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and higher baseline prevalence of cardiovascular disease and antihypertensives than never-use of LLD. LLD users had significantly thicker intima media layer, higher plaque prevalence, and a larger TPA. Change in risk factor levels over time is shown in Table 1 . In general, there was a favorable change in lipid levels from baseline to follow-up, most pronounced in long-term LLD group. Mean change (SD) in LDL-cholesterol was -2.22 (1.05) mmol/L in long-term users, -1.77 (1.11) mmol/L in any-time users, and -0.31 (0.79) mmol/L in never-users (P<0.0001). The proportion of daily smokers fell substantially in the whole cohort, whereas body mass index and diabetes mellitus prevalence increased. In multivariable-adjusted regression analysis, long-term use of LLD was an independent predictor for both ∆IMT (β=-0.0387 mm; P=0.0002) and ∆TPA (β=-0.400 mm 2 ; P=0.006), showing a protective effect against progression of atherosclerosis (Table 2) . Any-time use of LLD also showed a protective, but weaker effect on ∆IMT (β=-0.024 mm; P=0.046) and ∆TPA (β=-0.318 mm 2 ; P=0.06; 
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The main finding of our study was that long-term use of LLD, as well as any-time use of LLD, protected against progression of IMT and TPA during the 13 years observation time. The protective effect of long-term use of LLD on atherosclerosis progression was stronger than for any-time use of LLD, indicating a dose-response relationship. This coincided with a favorable change in lipid levels, most pronounced in longterm LLD users.
The study results imply that the effect of LLD on progression of carotid atherosclerosis seen in randomized clinical trials 3, 10, 14 and patient series 12,15 also applies to subjects belonging to the general population. A meta-analysis of 11 randomized controlled trials showed regression of IMT in 7 trials and slowing of progression in 4 trials, indicating a benefit of statin in early stages of the atherosclerotic process. 16 Another review showed that the strength of the statin effect on IMT was closely associated with reduction in LDL-cholesterol. 17 This is in accordance with our findings, where the reduction of LDL was greatest in the long-term users.
Progression of carotid IMT and TPA are correlated, but probably represent different atherosclerotic entities. Few clinical studies have studied the effect of statins on progression of carotid plaque burden, and most of these have been with small sample size. 9 One larger study used a plaque score method based on plaque presence and severity, and showed a significant difference in plaque score change between statin use and placebo, 18 and similar results have also been found for coronary plaque. 11 Statins were the dominating LLD in our study, whereas only 4 participants used a combination of statins and ezetimib, which has been found to be associated with regression of TPA, 15 but with increase in IMT. 19 A recent review of 9 randomized and 8 observational studies with number of participants ranging from 8 to 149 showed that statin treatment tended to halt plaque progression and increase plaque echogenicity. 9 We observed no effect of statins on plaque echogenicity (GSM) in our study.
Our study has some important weaknesses. The use of LLD in the population increased considerably over the 13-year study period. It can be questioned whether our estimates of use of LLD over time truly reflect the participants' use of LLD in the observation period. We calculated duration of use based on information from both questionnaires and lists of current medication at 3 points in time. Although previous studies have shown that repeated self-reported use of drug that are used regularly reflect chronic exposure, 20, 21 subjects may have failed to report use of LLD because they were not aware of the nature of the drug they were taking, and they could have forgotten to fill-in all brand names in the medication lists. The study results may have been influenced by selection bias caused by nonattendance at follow-up because of death, disease, or disability. 13 Progression of atherosclerosis may have been more pronounced and use of LLD more frequent in nonattendees. However, immortal time bias is avoided, 22 as the outcome variable is progression of atherosclerosis over a 13-year period, and can be measured in both users and nonusers of LLD. Progression of IMT is prone to measurement error, and is suggested as the reason for lack of association between progression of IMT and cardiovascular end points in a recent meta-analysis. 23 Use of 3-dimensional ultrasound to measure plaque volume could have increased the ability to demonstrate change in plaque burden. 24 The use of different ultrasonography equipment in the 4th and the 6th survey, and nonstandardized uptake angles is likely to have increased the measurement error. 25 Any such misclassification would affect the exposed and unexposed groups equally. Furthermore, misclassification both of the exposure to LLD and of progression of atherosclerosis would lead to underestimation of the true effect of use of LLD.
It has been debated whether statins have a role as a primary prevention tool for cardiovascular disease, or whether the effect is limited to secondary prevention in patients who manifest disease. [26] [27] [28] [29] In our study, use of LLD independently predicted slower progression of carotid atherosclerosis also in participants without prevalent cardiovascular disease. However, the observational study design does not allow inferences about whether the beneficial effect of LLD on atherosclerosis outweighs any possible negative effects of LLD in primary prevention.
The strengths of the study are the large study cohort, the population-based design, and a follow-up of >13 years, enabling us to assess whether the effect of LLD on atherosclerosis also applies to subjects treated outside the more rigorous terms of a randomized controlled trial.
In conclusion, our study shows that LLD slowed the progression of carotid atherosclerosis in the setting of a population-based observational study. The protective effect was strongest for long-term users.
Sources of Funding
The present study was supported by grants from the Northern Norway Regional Health Authority and from the Simon Fougner Hartmann's Family Foundation.
